Immunomax Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Immunomax General Information
Description
Operator of a biotech company intended to produce anti-cancer immune cell therapy. The company's developing homologous gamma delta CAR-T cell therapy and biopharmaceutical production animal cell lines, enabling healthcare professionals to help patient overcome diseases by strengthening immunity.
Contact Information
Website
www.immunomax.co.krCorporate Office
- 309, Industry-Academic Cooperation Building
- Science Campus, Korea University, 145 Anam-ro, Seongbuk-gu
- Seoul, 02841
- South Korea
Corporate Office
- 309, Industry-Academic Cooperation Building
- Science Campus, Korea University, 145 Anam-ro, Seongbuk-gu
- Seoul, 02841
- South Korea
Immunomax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Mar-2026 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Feb-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 29-Jun-2017 | $884K | $884K | Completed | Generating Revenue | |
| 1. Seed Round | 01-Oct-2016 | Completed | Startup |
Immunomax Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immunomax Patents
Immunomax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024151124-A1 | Method for producing memory t cell-derived immune cell therapy with excellent anticancer ability | Inactive | 12-Jan-2023 | ||
| JP-2025501332-A | Method for expanding and culturing gamma delta t cells | Active | 03-Jan-2022 | ||
| JP-7802941-B2 | Method for expanding and culturing gamma delta t cells | Active | 03-Jan-2022 | ||
| EP-4461809-A1 | Method for expansion culture of gamma-delta t cell | Inactive | 03-Jan-2022 | ||
| EP-4461809-A4 | Method for expansion culture of gamma-delta t cell | Inactive | 03-Jan-2022 | C12N5/0636 |
Immunomax Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immunomax Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hana-Magna | Other | Minority | ||
| Shinhan Capital | Venture Capital | Minority | ||
| SV Investment | Venture Capital | Minority | ||
| UTC Investment | Asset Manager | Minority |
Immunomax FAQs
-
When was Immunomax founded?
Immunomax was founded in 2015.
-
Where is Immunomax headquartered?
Immunomax is headquartered in Seoul, South Korea.
-
What is the size of Immunomax?
Immunomax has 14 total employees.
-
What industry is Immunomax in?
Immunomax’s primary industry is Drug Discovery.
-
Is Immunomax a private or public company?
Immunomax is a Private company.
-
What is Immunomax’s current revenue?
The current revenue for Immunomax is .
-
How much funding has Immunomax raised over time?
Immunomax has raised $884K.
-
Who are Immunomax’s investors?
Hana-Magna, Shinhan Capital, SV Investment, and UTC Investment have invested in Immunomax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
